SCHEMBL25169342

SCHEMBL25169342

Cc1ccc(S(=O)(=O)n2nc(C)c3c(Cl)cc(Br)cc32)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.47
POLB P06746 1/20 0.43
KMT2A Q03164 8/20 0.42
MEN1 O00255 6/20 0.42
ALDH1A1 P00352 3/20 0.42
LMNA P02545 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
SLC9A1 P19634 1/20 0.42
TP53 P04637 1/20 0.42
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
ALOX12 P18054 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GAA P10253 1/20 0.39
MAPK1 P28482 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
THRB P10828 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25172322 0.86 MAPT (0.48) MAPTPOLBKMT2AMEN1ALDH1A1
SCHEMBL2144861 0.80 MAPT (0.50) MAPTPOLBKMT2AMEN1ALDH1A1
SCHEMBL1272497 0.77 MAPT (0.50) MAPTPOLBKMT2AMEN1ALDH1A1
SCHEMBL16752265 0.76 MAPT (0.49) MAPTPOLBKMT2AMEN1ALDH1A1
SCHEMBL14663158 0.75 MAPT (0.47) MAPTPOLBKMT2AMEN1ALDH1A1
SCHEMBL28075049 0.74 SLC9A1 (0.50) MAPTPOLBKMT2AMEN1ALDH1A1
SCHEMBL12253486 0.74 SLC9A1 (0.56) MAPTPOLBKMT2AMEN1ALDH1A1
SCHEMBL1100213 0.72 MAPT (0.47) MAPTPOLBKMT2AMEN1ALDH1A1
SCHEMBL21195904 0.69 MAPT (0.47) MAPTPOLBKMT2AMEN1ALDH1A1
SCHEMBL1099865 0.69 MAPT (0.57) MAPTPOLBKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260069571-A1 DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES REDX PHARMA PLC (GB) 2026-03-12 US disclosed
EP-4426688-B1 DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES REDX PHARMA LTD (GB) 2025-12-03 EP disclosed
EP-4426688-A1 DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES Redx Pharma Plc (GB) 2024-09-11 EP disclosed
CN-118201918-A DDR1 and DDR2 inhibitors for the treatment of cancer and fibrotic diseases 莱德克斯制药公共有限公司 2024-06-14 CN disclosed
WO-2023079291-A1 DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES REDX PHARMA PLC (GB) 2023-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260069571-A1 DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES DDR1, DDR2, TGFBR2 MAPT 4765/4885POLB 3719/4885KMT2A 3962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.